Repligen (RGEN) M&A announcement summary

Deal rationale and strategic fit

• Acquisition of BioLife Solutions for $1.5 billion accelerates leadership in the fast-growing cell therapy market, adding a highly complementary and differentiated portfolio, including a market-leading biopreservation media platform and cell processing tools.

• BioLife's products, especially CryoStor, are deeply embedded in commercial cell therapies and clinical trials, enhancing the combined offering and customer reach.

• The deal supports a strategy to double company size over the medium term, creates new verticals for future M&A, and provides a platform for future organic and inorganic growth.

• Strategic adjacency in the bioprocessing ecosystem, maintaining focus while entering a high-growth vertical and strengthening the combined entity's position.

• Shared culture of innovation and customer centricity expected to drive future growth and value creation.

Financial terms and conditions

• Total consideration is $1.5 billion: 36% cash ($564 million) and 64% stock (7.2 million shares), valuing BioLife at $31 per share, with $11.25 in cash and 0.1442 shares of common stock per BioLife share, a 24% premium to 90-day VWAP.

• Pro forma cash post-deal will exceed $300 million, with net leverage at approximately 1x.

• The transaction is accretive to revenue growth, margins, and adjusted EPS in year one.

• BioLife's 2025 revenue was $96 million, with 29% pro forma growth.

• BioLife stockholders receive immediate cash value and opportunity to participate in future growth.

Synergies and expected cost savings

• At least $20 million in year one synergies, rising to over $30 million in year two, from public company, G&A, supply chain, and manufacturing efficiencies.

• 75% of synergies from operating expenses, 25% from cost of goods sold.

• Integration expected to deliver $0.05 adjusted EPS accretion in year one and $0.25+ in year two.

• Additional upside anticipated from cross-selling and revenue synergies, especially in Asia-Pacific.

• Modest revenue synergies assumed, with potential for future upside.